Without more innovation à la Dupixent, Regeneron could be in trouble: Report

25th September 2019 Uncategorised 0

Why has Regeneron’s stock collapsed more than 30% since March? Analysts at SVBLeerink say the company has lost its edge in antibody development—and investors are recognizing that its growth potential may be limited as a result.

More: Without more innovation à la Dupixent, Regeneron could be in trouble: Report
Source: fierce